3-(4-nitrophenyl)-2H-phthalazine-1,4-dione profile

ID Source	ID
PubMed CID	683963
CHEMBL ID	1445259
CHEBI ID	113081
SCHEMBL ID	265592

Synonym
OPREA1_038626
OPREA1_282749
MLS000689129 ,
smr000283114
CBDIVE_002012
OPREA1_366583
2-(4-nitrophenyl)-2,3-dihydrophthalazine-1,4-dione
STK024477
CHEBI:113081
AKOS000485811
3-(4-nitrophenyl)-2h-phthalazine-1,4-dione
HMS2723F17
CHEMBL1445259
F1443-5183
93716-69-9
SCHEMBL265592
4-hydroxy-2-{4-nitrophenyl}-1(2h)-phthalazinone
AG-690/34981044
cid_683963
bdbm54926
3-(4-nitrophenyl)-2h-phthalazine-1,4-quinone
Q27193545
SR-01000509946-1
sr-01000509946
2-(4-nitrophenyl)-2,3-dihydro-1,4-phthalazinedione

Class	Description
phthalazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	39.8107	0.6310	35.7641	100.0000	AID504339
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	39.8107	5.6234	17.2929	31.6228	AID485281
acid sphingomyelinase	Homo sapiens (human)	Potency	79.4328	14.1254	24.0613	39.8107	AID504937
glp-1 receptor, partial	Homo sapiens (human)	Potency	5.0119	0.0184	6.8060	14.1254	AID624417
WRN	Homo sapiens (human)	Potency	50.1187	0.1683	31.2583	100.0000	AID651768
GLS protein	Homo sapiens (human)	Potency	12.5893	0.3548	7.9355	39.8107	AID624170
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	10.0000	0.2818	9.7212	35.4813	AID2326
chromobox protein homolog 1	Homo sapiens (human)	Potency	50.1187	0.0060	26.1688	89.1251	AID540317
transcriptional regulator ERG isoform 3	Homo sapiens (human)	Potency	31.6228	0.7943	21.2757	50.1187	AID624246
DNA polymerase beta	Homo sapiens (human)	Potency	39.8107	0.0224	21.0102	89.1251	AID485314
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	16.8336	0.1683	16.4040	67.0158	AID720504
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	39.8107	0.1000	28.9256	213.3130	AID588591
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	10.0000	0.0501	27.0736	89.1251	AID588590
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	89.1251	0.0316	22.3146	100.0000	AID588579
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	10.0000	0.0041	9.9625	28.1838	AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
plectin 1	Homo sapiens (human)	IC50 (µMol)	75.6167	1.5180	6.4106	15.6610	AID1817; AID2127; AID2141
X-linked inhibitor of apoptosis	Homo sapiens (human)	IC50 (µMol)	20.0000	0.3130	0.3130	0.3130	AID1513
neutrophil cytosol factor 1	Homo sapiens (human)	IC50 (µMol)	5.2200	0.3900	6.5441	29.1200	AID1275
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID779919	Inhibition of PARP-1 (unknown origin) at 1 uM after 60 mins by colorimetric assay relative to control	2013	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21	Identification of novel PARP-1 inhibitors by structure-based virtual screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
1,4-Dihydrothieno[3,2-d]pyrimidin-4-one [no description available]	2.08	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1

3-(4-nitrophenyl)-2H-phthalazine-1,4-dione

Cross-References

Synonyms (25)

Drug Classes (1)

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Bioassays (15)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.29

Study Types

3-(4-nitrophenyl)-2H-phthalazine-1,4-dione

Cross-References

Synonyms (25)

Drug Classes (1)

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Bioassays (15)

Research

Studies (7)

Market Indicators

Research Demand Index: 12.29

Study Types

Related Drugs (1)

Related Conditions (4)